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A B S T R A C T
Human herpesvirus type 6-(HHV-6) has been associated with morbidity after liver 
transplantation.
Objective: The aim of this study was to determine the HHV-6 seroprevalence among donor-
recipient pairs, analyze the incidence of early active infection, its clinical manifestation, 
interaction with CMV, and the related morbidity in the first year after kidney transplantation. 
Methods: 46 donor-recipient pairs had IgG evaluated by ELISA before transplantation: HHV-6-
(Pambio – USA) and CMV-(Roche – USA). A frozen whole blood sample collected weekly (from 
the 1st to the 6th week) was retrospectively tested for HHV-6 viral load (VL) determination by real 
time quantitative PCR (qPCR, Nanogen – Italy). Patients were preemptively surveyed for CMV by 
pp65 antigenemia (Ag, APAAP, immunohistochemistry, Biotest – Germany) from the 4th to the 
12th week after transplantation. Active infection was defined as qPCR-HHV6+ (viral-load/mL-VL) 
and Ag+ (+cells/100.000 granulocytes), for HHV-6 and CMV, respectively. DCMV was defined as 
simultaneous positive antigenemia and suggestive signs/symptoms. Concerning +qPCR-HHV6, 
associated factors, clinical manifestation, interaction with CMV and morbidity were searched. 
Results: Pre-transplant HHV-6 seroprevalence was significantly higher among kidney 
recipients compared to their donors (82.6x54.8%; p = 0.005 [3.9 (1.4-10.4)]). Active infection 
by this virus occurred in 26.1% (12/46), with no association with previous IgG (p = 0.412). 
Median VL was 125 copies/mL (53-11.264), and the median Ag was 21 +cells (2-740). There 
was no association between HHV-6 and CMV activation after transplantation (p = 0.441), 
neither concerning DCMV (p = 0.596). Median highest Ag+ and days of ganciclovir treatment 
were similar between qPCR-HHV6 + or − (p = 0.206 and p = 0.124, respectively). qPCR-HHV6+ 
was associated with higher incidence of bacterial (p =  0.009) and fungal (p = 0.001) 
infections, and higher number (p = 0.001) of hospital admission and longer duration of 
hospitalization over the first 6 and 12 months post-transplantation (p = 0.033 and p = 0.001). 
Conclusion: Latent HHV-6 infection is more common among recipients than donors before 
transplantation. Early active infection by this pathogen after transplantation does not 
increase DCMV incidence or severity during the first 3 months of follow-up. However, early 
HHV-6 replication is associated with other infections and hospitalizations in the first year.
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Introduction
Viral infections are one of the major causes of morbidity 
and mortality after organ and tissue transplants. Besides 
the etiological agent, the risk of a viral infection depends on 
the pathogen epidemiology and host’s immunity. Because 
transplants imply the use of immunosuppressant drugs to 
avoid graft rejection, the diagnosis of a viral infection relies 
on its kinetics and clinical suspicion, frequently before signs/
symptoms. One of the most studied families of virus in 
transplantation is the Herpesviridae, which encompasses eight 
different viruses. The majority of them are highly prevalent 
in the general population and shows an immunomodulatory 
effect.1-5
The deleterious role of the cytomegalovirus (CMV) after 
transplantation is well recognized, and its active replication 
is systematically checked. Initially, this active infection was 
associated with high mortality and morbidity.1-10 These were 
the reasons that brought about the current practice of early 
diagnosis and treatment in risk populations. Nowadays, the 
morbidity and cost related to the specific antiviral treatment 
are still major concerns. In addition, late recurrences of CMV, 
slow decrease of viral replication rate, or even drug resistance 
have concerned clinicians.11-15
CMV replication has been surveyed after kidney, kidney-
pancreas, lung, liver, heart, and hematopoietic stem cell trans-
plantations in order to avoid end-organ disease.3,13,15-21 In our 
hospital, a preemptive strategy for CMV was introduced in 
1993 using antigenemia (Ag) from the 4th to 12th week post-
solid organ transplantation and whenever there is clinical 
suspicion. Based on this, the cumulative incidence of probable 
CMV disease (pCMVD) in the first 3 months, among kidney 
recipients, has ranged from 27-38%, and severe cases have not 
been frequent.3,13
Nevertheless, there can be sporadic patients subjected to 
more than 21 days of intravenous ganciclovir; cases with low 
cellularity on Ag showing signs/symptoms; and, sometimes, 
unusual clinical manifestations for patients being preemptively 
surveyed (as severe bone marrow suppression or central 
nervous systems involvement). These observations raised 
the hypothesis that another viral agent could be implicated, 
such as HHV-6, which also has a known immunomodulatory 
potential.1,5,7,18-23
HHV-6, as other herpesviruses, can remain latent in the 
host’s cells and reactivate as soon as the immunosuppression 
starts. Usual sites for latency after primary infection include 
salivary glands, lymph nodes, mononuclear cells, and liver and 
renal parenchyma.6 Clinically, HHV-6 causes a mononucleosis-
like syndrome, lymphadenopathy, hepatitis, bone marrow 
suppression, interstitial pneumonitis, and severe focal 
encephalitis, well-reported in liver transplant recipients.4,7,8 
Understanding that the epidemiology and the clinical role 
of the latent and early-active HHV-6 infection after kidney 
transplantation are not clear, we designed this study. The purpose 
was to determine HHV-6 seroprevalence in donor-recipient pairs, 
the incidence of early viral replication after kidney transplant, its 
clinical repercussion, interaction with CMV, and association with 
morbidity during the first year after transplantation. 
Patients and methods
This was a cohort study that included all the adult kidney 
transplants performed between April and September/2002 
in a tertiary hospital, which is a national reference for 
transplants (n = 46).
There, donor’s and recipient’s serology, collected 
before transplantation, were analyzed for latent infection 
determination. HHV-6 active infection was described as viral 
load (VL) measured by real time quantitative polymerase chain 
reaction (qPCR-HHV6) in peripheral blood collected between 
the 1st and 6th weeks and frozen at −80°C. 
Patients were surveyed preemptively, as routine, with serial 
CMV-Ag from the 4th to the 12th week post-transplantation. 
Intravenous ganciclovir was administered prophylactically 
during 14 days in CMV-IgG negative recipients (n = 3). CMV 
active infection was defined as CMV-Ag+, and pCMVD was 
defined as more than ten +cells on Ag independent of the 
signs/symptoms or increasing number of +cells combined 
with signs/symptoms, according to our previous study.13 
Treatment was also performed using intravenous ganciclovir 
for 14 days or more, until Ag became negative. 
Donor and recipient demographic data (age and gender) 
and transplant characteristics (donor source, isolated kidney/
simultaneous pancreas-kidney, cold ischemia time, initial 
immunosuppression, induction therapy and delayed graft 
function) were analyzed. Delayed graft function was defined as 
the necessity for dialysis in the first week post-transplantation. 
Clinical and laboratory parameters studied that could 
be associated with HHV-6 included: total leukocytes 
and lymphocytes (1st-6th week), liver enzymes (aspartate- and 
piruvate-amminotransferase, 1st-12th week). Serum creatinine 
levels were evaluated as a graft function marker (1st-12th weeks, 
monthly until the 6th month, and annually until 4th year). 
Morbidity in the first year was evaluated by: biopsy-proven acute 
graft rejection, development of other infections (non-HHV-6 and 
non-CMV), hospital admission (number and duration), and graft 
loss and death. Information was taken from medical records. 
The variables above described were compared, qualitative 
and quantitatively, as indicated, between patients who 
developed HHV-6 active infection (+qPCR-HHV6) and those who 
remained negative. In order to avoid a bias due to CMV infection, 
all comparisons were performed between positive and negative 
patients, as follows: a) HHV-6 active infection (qPCR-HHV6+), 
b) CMV active infection (CMV-Ag+) and c) active infection by 
both viruses (qPCR-HHV6 + CMV-Ag+) after transplantation, 
each one analyzed during its higher risk period. 
For the study of HHV-6 latent and early replication effects 
upon CMV infection, the following associations were analyzed: 
a) incidence of CMV active infection, b) incidence of pCMVD and 
c) pCMVD severity (highest Ag+ and days of ganciclovir treatment). 
This study was approved by the institutional Ethics Committee, 
and all patients included signed an informed consent. 
HHV-6 and CMV serology
Immunoenzimatic test (ELISA) for specific IgG was performed 
in the sera of all donor-recipient pairs collected before the 
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transplant, either for HHV-6 (Pambio – USA) and CMV (Roche – 
USA). Inconclusive results were repeated, and those that 
remained undetermined were excluded from the analysis 
(inconclusive HHV6-IgG: n = 4 donors).
CMV pp65 antigenemia (CMV-Ag)
Antigenemia was performed in blood samples collected with 
EDTA by immunohistochemistry method after granulocyte 
isolation. A monoclonal antibody (C10/C11) directed against 
pp65 CMV matrix protein was applied (APAAP, Biotest – 
Germany). This test gives a quantitative result, indicating 
the number of positive cells that represent those with viral 
replication (+cells/105 granulocytes). 
HHV-6 quantitative real time PCR (qPCR-HHV6)
HHV-6 VL was determined by qPCR using DNA extracted 
(Invisorb, Spin Blood mini kit, Invitek – Germany) from whole 
blood collected with EDTA. A commercial kit for HHV-6 (HHV-
6Q-PCR Alert AmpliMIX, Nanogen – Italy) was used in an 
ABI Applied Biosystems 7300 device. This test is a multiplex 
reaction, including an internal control (human β-globin gene) 
simultaneously amplified with the HHV-6 ORF13R region as 
target. This region is common for both variants of HHV-6 (A 
and B). The standard-curve has four known quantitative points 
of VL (102,103,104, 105), allowing a precise quantification of the 
initial sample VL. The limit for detection is 40 copies/reaction. 
The provided software for analysis shows the following results: 
a) negative, b) < 2000 copies/mL and c) absolute number of 
copies when ≥ 2000 copies/mL. For the purposes of this study, 
the following formula was applied to determine absolute number 
of copies in positive samples showing VL < 2000 copies/mL: cN 
(initial copy number in the sample) = Fe (unit for VL description in 
the sample; 1mL) x eE (extraction method equivalent efficiency; 
1/1,0=1) x Fa (extracted and amplified DNA volume ratio; 
200µL/5µL = 40) x number of copies (VL obtained in the reaction).
Statistical analysis
Variables were described as percentage, mean and standard 
deviation (SD), or median. Chi-square with Yates correction 
or Fisher’s exact and Student’s t test or Mann-Whitney 
was applied, as indicated, using the Statistical Package for 
Social Sciences (SPSS 14.0) software. p ≤ 0.05 was considered 
significant, being described the respective relative risk (RR) and 
95% confidence interval (95% CI).
Results
Pre-transplant HHV-6 and/or CMV latent infection 
Prevalence of HHV-6 latent infection was significantly higher 
among recipients than donors (recipients: 82.6% [38/46] x 
donors: 54.8% [23/42], respectively; p = 0.005; RR = 3.9 [1.4-10.4]). 
CMV-IgG seroprevalence was similar between the groups at 
the time of transplantation (recipients: 93.5% [43/46] x donors: 
84.8% [39/46]; p = 0.315).
Post-transplant HHV-6 and/or CMV active infection 
HHV-6 active infection occurred in 26.1% (12/46) of the 
recipients during the first six weeks of transplantation. 
Primary infection was seen in 37.5% (3/8) of the HHV-6-IgG 
negative, and reactivation and/or reinfection in 23.7% (9/38) 
of the IgG+ patients (p = 0.412). Median VL was 125 copies/mL 
(53-11.264), mostly showing < 2000 copies/mL (83.3% [10/12]). 
HHV-6 latent infection did not significantly change the 
incidence of: a) HHV-6 active infection (IgG+: 23,7% [9/38] x 
IgG-: 37,5% [3/8]; p = 0,412); b) CMV active infection (HHV-6 
IgG+: 76.0% [29/38] x IgG-: 75.0% [6/8]; p = 0.999) and c) pCMVD 
(HHV-6 IgG+: 42.0% [16/38] x IgG-: 50.0% [4/8]; p = 0.713).
There was also no association between early active 
replication of HHV-6 and later CMV-Ag+ (qPCR+: 66.7% 
[8/12] x qPCR-: 79.0% [27/34]; p = 0.441) or pCMVD (qPCR+: 
50.0% [6/12] x qPCR-: 41.2% [14/34]; p = 0.596). Elevated 
CMV-Ag+ was also not associated with HHV-6 active 
infection, neither among patients who developed pCMVD 
(qPCR+: 93[6-600] x qPCR-: 53[15-740]+cells; p = 0.857) nor 
among those who did not develop (qPCR+: 7[3-11] x qPCR-: 
5[2-12]+cells; p = 0.387). The mean duration of ganciclovir 
treatment for pCMVD was similar between patients 
who previously had + or − qPCR-HHV6 respectively 
(18.2+3.8 x 15.5+3.0 days; p = 0.124).
CMV viremia occurred in 76.1% (35/46) of the recipients. 
The CMV-IgG negative transplanted patients needed 
additional ganciclovir treatment, despite the intravenous 
prophylaxis with the same drug administered during 
the first 14 days post-transplantation. Among CMV-
IgG+ patients, 74.4% (32/43) developed Ag+ (IgG-:100.0% 
x IgG+:74.4%; p = 0.999). pCMVD occurred in 43.5% (20/46), 
being 100.0% among those who had primary infection 
and 39.5% among those who reactivated and/or had 
reinfection after transplantation (IgG-:3/3 x IgG+: 17/43; 
p = 0.075). Median highest Ag+ was 21 +cells (2-740), being 
65 +cells (6-740) and 5 +cells (2-12) among patients with or 
without pCMVD, respectively (p = 0.001). 
Active infection by both viruses occurred in 17.4% (8/46) of 
the recipients during the first 3 months, but 15.2% (n = 7) became 
always negative for both, and 8.7% (n = 4) had only qPCR-HHV6+. 
Additional 58.7% (n = 27) of the sample had only CMV-Ag+. 
Associated factors with active viral replication after 
transplantation 
Table 1 presents the general transplant characteristics and their 
association with active infection by HHV-6, CMV, or both, after 
kidney transplant. Mean age was similar between positive or 
negative qPCR-HHV6 after transplantation (qPCR+: 32.7 ± 13.9 
x qPCR-: 39.1 ± 13.7 years; p = 0.178), and also between double 
positive HHV-6+CMV along the first weeks than the others (+:38.4 
± 13.6 x -:37.2 ± 14.2; p = 0.836). CMV-Ag positivity occurred more 
frequently among older patients at the time of transplantation 
(Ag+:40.4 ± 13.7 x Ag-:28.0 ± 10.0; p = 0.008). Gender (male 23/46, 
50.0%) and cold ischemia time (21.5 ± 6.9 hours [12.2-36.0]) 
were not different between patients + or − for HHV-6, CMV 
or both infections (data not shown). Donor source, kidney or 
simultaneous pancreas-kidney transplant, induction therapy, and 
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Transplant  
demographics 
 
 
Total 
(n = 46) 
n (%) 
 
                    HHV-6*                     CMV**          +HHV-6 → +CMV***
Positive 
(n = 12) 
n (%)
Negative 
(n = 34) 
n (%)
p 
 
Positive 
(n = 35) 
n (%)
Negative  
(n = 11) 
n (%)
p 
 
Yes  
(n = 8) 
n (%)
No  
(n = 38) 
n (%)
p 
 
Deceased donor 27 (58.7%) 5 (41.7) 14 (41.2) 0.976 13 (37.1) 6 (54.5) 0.307 3 (37.5) 16 (42.1) 0.999
Simultaneous pancreas- kidney 
transplantation
3 (6.5%) 2 (16.7) 1 (2.9)
0.162 1 (2.8) 2 (18.2) 0.138 1 (12.5) 2 (5.3) 0.444
Induction therapy 18 (39.1%) 5 (41.7) 13 (38.2) 0.834 14 (40.0) 4 (36.4) 0.999 3 (37.5) 15 (39.5) 0.999
Initial immunosuppression 0.282 0.083 0.937
 CyA-MMF-Pr 26 (56.5) 5 (41.7) 21 (61.8) 23 (65.7) 3 (27.3) 4 (50.0) 22 (57.8)
 CyA-Aza-Pred 14 (30.4) 4 (33.3) 10 (29.4) 9 (25.7) 5 (45.4) 3 (37.5) 11 (28.9)
 Rapa-FK-Pred 4 (8.7) 2 (16.7) 2 (5.9) 2 (5.7) 2 (18.2) 1 (12.5) 3 (7.9)
 CyA-Aza 1 (2.2) 1 (8.3) 0 1 (2.9) 1 (9.0) 0 1 (2.7) 
 MMF-FK 1 (2.2) 0 1 (2.9) 1 (2.9) 0 0 1 (2.7) 
Drugs
 MMF 27 (58.7) 5 (41.7) 22 (64.7) 0.163 24 (68.6) 3 (27.3) 0.032α 4 (50.0) 23 (60.5) 0.700
 Aza 15 (32.6) 5 (41.7) 10 (29.4) 0.436 9 (25.7) 6 (54.5) 0.075 3 (37.5) 12 (31.5) 0.999
 CyA 5 (10.9) 10 (83.3) 31 (91.2) 0.594 32 (91.4) 9 (81.8) 0.580 7 (87.5) 34 (89.5) 0.999
 FK 5 (10.9) 2 (16.7) 3 (8.8) 0.594 3 (8.6) 2 (18.2) 0.580 1 (12.5) 4 (10.5) 0.999
 Sirolimus 5 (10.9) 2 (16.7) 3 (8.8) 0.594 2 (5.7) 3 (27.2) 0.080 1 (12.5) 4 (10.5) 0.999
Delayed graft function# 22 (47.8) 5 (417) 17 (50.0) 0.619 17 (37.7) 5 (45.4) 0.857 3 (37.5) 19 (50.0) 0.702
*Comparison between patients with and without HHV-6 active infection (qPCR-HHV6) from 1st to 6th weeks after transplantation; **comparison 
between patients with and without CMV active infection (CMV-Ag) from 4th to 12th weeks post-transplantation; ***comparison between patients 
who had both active viral infections after transplantation (HHV-6 and CMV); CyA, cyclosporine; MMF, mofetil micofenolate; Pred, prednisone; 
Rapa, sirolimus; FK, tracrolimus; Aza, azatioprine; #necessity for dialysis in the first week after transplantation; αRR = 2.5 (0.9-6.7).
Table 1 - Transplant demographic data and their association with active infection caused by HHV-6, CMV or both after 
kidney transplantation 
delayed graft function were not associated with HHV-6, CMV or 
both viral replications during the follow-up.
The distribution of different combinations of drugs for initial 
immunosuppression was not different between patients with 
or without active infection by HHV-6, CMV, or both. However, 
mofetil mycofenolate (MMF) appeared to be more frequently 
associated with the CMV replication (p = 0.032; RR = 2.5[0.9-6.7]).
Clinical outcomes related to the post-transplant active infections 
by HHV-6, CMV or both 
Laboratory parameters analyzed in this study were not 
associated with HHV-6 infection, neither qPCR-HHV6+ nor 
HHV-6+CMV. Patients who had CMV-Ag+ showed higher 
serum creatinine at the following moments compared 
to those who remained negative for this virus: on the 6th 
week post-transplantation (1.9 ± 0.8 versus 1.3 ± 0.4 mg/dL; 
p = 0.038), on the 7th (1.7 ± 0.6 x 1.3 ± 0.4 mg/dL; p = 0.037), on the 
10th (1.5 ± 0.5 x 1.2 ± 0.3 mg/dL; p = 0.034) and on the 12th 
(1.6 ± 0.5 x 1.2 ± 0.3 mg/dL; p = 0.018). 
Table 2 describes first year post-kidney transplant clinical 
outcomes, presenting cumulative incidences and their 
distributions according to the early viral infection: HHV-6, CMV 
or both, respectively. 
qPCR-HHV6+ was associated with higher incidence of 
other infections in the first year after transplantation (qPCR+: 
100% x qPCR-: 67.6%; p = 0.044; RR = 1.5[1.1-1.9]), mainly 
caused by: bacteria (qPCR+: 100% x qPCR-: 58.8%; p = 0.009; 
RR = 1.6[1.2-2.0]) and fungi (qPCR+: 66.7% x qPCR-: 11.8%; p = 0.001; 
RR = 5.6[2.0-15.3]). Even though there was no case of 
deep mycosis, the only two cases that achieved HHV-6 VL 
≥ 2000 copies/mL presented fungal diseases and severe 
bacterial infections. 
CMV viremia was associated with higher incidence of 
other viral infections (non-HHV-6 and non-CMV) (p = 0.000, 
RR = 2.7[1.2-6.0]). These other viral infections were not 
dependent on the MMF initial immunosuppression (MMF: 
92.6% [25/27] x no MMF: 57.9% [14/19]; p = 0.107). In this 
series, viral infections (non-HHV6 and non-CMV) were 
diagnosed based on clinical and laboratory findings, 
including: human papillomavirus, simplex herpesvirus (types 
1 and 2), varicella-zoster virus (both clinical presentations), 
upper respiratory viral infections, Verruca vulgaris, Molluscum 
contagiosum, and meningitis. Bacterial clinical syndromes 
observed along the follow-up included: piodermitis, wound 
infection, arteriovenous fistulae infection, cystitis, prostatitis, 
graft’s acute pyelonephritis, perirenal abscess, sinusitis, 
bronchopneumonia, spontaneous bacterial peritonitis, 
and sepsis. Fungal infections were, respectively: genital 
candidiasis, Tinea cruris, dermatophytosis, and onicomycosis.
The single case of viral meningitis had no etiological 
definition and occurred in a diabetic recipient of 
simultaneous pancreas-kidney transplant. This patient 
had received daclizumab induction therapy and combined 
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immunosuppression with sirolimus, tacrolimus and MMF. She 
developed pCMVD and several bacterial infections, some of 
them very severe, but never showed early qPCR-HHV6+ in the 
follow-up screening. 
Duration of hospitalization after transplant surgery was 
similar for patients who did or did not develop HHV-6 and/or CMV 
replication thereafter. On the other hand, patients who had qPCR-
HHV6+ during the first 6 weeks after transplantation had more 
hospitalizations  with longer duration at 6th and 12th months 
post-transplantation. These outcomes were not associated with 
CMV viremia. These results can be seen in Table 2. 
Besides qPCR-HHV6+, viral (p = 0.001) and fungal infections 
(p = 0.002) were associated with more hospitalizations in the 
first year, whereas the use of initial immunosuppression 
including prednisone showed an inverse association 
(with prednisone: 2.9+1.4 x without: 5.5+0.7; p = 0.023). 
However, different infectious agents were associated with 
duration of hospitalization at 6 or 12 months, respectively: 
bacterial: p = 0.058 and p = 0.022; viral: p = 0.001 and p = 0.001; 
fungal: p = 0.004 and p = 0.011. pCMVD was an independent risk 
factor for bacterial and viral infection in univariate analysis 
bacterial: RR = 1.9[1.2-2.8]; p = 0.001 and viral: RR = 1.3[1.0-1.7]; 
p = 0.014). 
Graft loss and death were not associated with the studied 
viral infections (HHV-6, CMV or both). In this series, patients 
returned to dialysis (n = 6; 13.0%) only after the fourth year 
of transplantation, all due to chronic allograft nephropathy. 
Among the other six (13.0%) patients who died during the 
study, three (50.0%) died during the first year: one had sepsis 
due to spontaneous bacterial peritonitis, the second had a 
cardiac arrest and the third died by external cause (trauma), 
in the presence of stable graft function.
Discussion
In the last decade, HHV-6 has become increasingly important, 
mainly as an emergent or co-pathogen in complex diseases. It 
is possible that transplants with higher immunological risk that 
have been performed using numerous new immunosuppressant 
agents could have contributed to the emergency of a new 
pathogen potentially dangerous to the graft or host.1,5,7,18,23 
HHV-6 can be one of them, and can compromise the clinical 
outcome of the transplant. This virus has been studied especially 
among liver and hematopoietic stem cell recipients. Its role in 
kidney transplant is not yet clear. 
Our healthy population represented by organ donors 
showed a marginally lower incidence of latent infection by 
this virus when compared to North American reports (55% 
x 59-100%).4,5,9,15,18 It was significantly lower than the rate 
observed among kidney transplant recipients immediately 
before engraftment, which could be explained by the relative 
immunosuppression conferred by chronic renal disease and 
hemodialysis.1,5 Nevertheless, the prevalence of HHV-6 latent 
infection before kidney transplantation in our study was 
similar to that described for kidney and liver recipients in other 
centers.22 It should be pointed out that HHV-6 serology before 
transplantation was not as helpful as CMV-IgG determination 
for predicting subsequent viral active infection, as suggested 
by others, needing confirmation with bigger studies.1,3,5,7,18 
First year clinical 
outcomes 
 
 
Total 
(n = 46) 
n (%) 
 
                   qPCR-HHV6                        CMV-Ag             +HHV-6 → +CMV ***
Positive 
(n = 12) 
n (%)
Negative 
(n = 34) 
n (%)
p 
 
Positive 
(n = 35) 
n (%)
Negative  
(n = 11) 
n (%)
p 
 
Yes  
(n = 8) 
n (%)
No  
(n = 38) 
n (%)
p 
 
Acute rejection 26 (56.5) 9 (75.0) 17 (50.0) 0.183 17 (48.6) 9 (81.8) 0.082 5 (62.5) 21 (55.3) 0.999
Other infections:
General 33 (71.7) 12 (100.0) 23 (67.6) 0.044δ 25 (71.4) 8 (72.7) 0.999 6 (75.0) 27 (71.0) 0.999
Bacterial 32 (69.5) 12 (100.0) 20 (58.8) 0.009ε 23 (65.7) 9 (81.8) 0.460 8 (100.0) 24 (63.1) 0.085
Viral 39 (84.8) 11 (91.7) 28 (82.3) 0.657 35 (100.0) 4 (36.4) 0.001α 8 (100.0) 31 (81.5) 0.325
Fungal 12 (26.1) 8 (66.7) 4 (11.8) 0.001β 10 (2.8) 2 (18.2) 0.701 6 (75.0) 6 (15.8) 0.002γ
Hospital admissions 
(median, minimum-maximum)
 
 No in the 1st year 3.0 (1-6) 4.0 (2-6) 2.5 (1-6) 0.001 3.0 (1-6) 2.0 (1-5) 0.103 4.5 (3-6) 3.0 (1-6) 0.001
 Surgical admission (days)* 20.0 (7-69) 19.5 (14-69) 20.5 (7-57) 0.688 20.0 (7-69) 20.0 (14-57) 0.897 18.0 (14-69) 21.0 (7-57) 0.459
 1st 6 months (days) 33.5 (14-108) 40.0 (25-108) 29.5 (14-104) 0.033 40.0 (15-108) 25.0 (14-99) 0.094 50.5 (25-108) 31.5 (14-104) 0.049
 1st year (days) 42.5 (14-156) 80.0 (33-120) 29.5 (14-156) 0.001 45.0 (15-156) 25.0 (14-99) 0.226 85.0 (40-120) 31.5 (14-156) 0.002
Graft loss# 12 (26.1) 3 (25.0) 9 (26.5) 0.999 10 (28.6) 11 (18.2) 0.701 1 (12.5) 11 (28.9) 0.660
Death# 6 (13.0) 4 (11.8) 2 (16.7) 0.644 5 (14.3) 1 (9.0) 0.999 1 (12.5) 5 (13.1) 0.999
CMV-Ag, CMV antigenemia from 4th to 12th weeks post-transplantation; positive CMV-Ag, active infection; qPCR-HHV6, quantitative real time 
PCR for HHV-6; positive qPCR-HHV6, active infection; *hospitalization for transplantation; #outcome analyzed until 2009; RR, relative risk; 95% CI; 
αRR = 2.7 (1.2-6.0); βRR = 5.6 (2.0-15.3); γRR = 4.7 (2.1-10.9); δRR = 1.5 (1.1-1.9); εRR = 1.6 (1.2-2.0).
Table 2 - First year clinical outcomes according to occurrence of post-transplant active viral infection: HHV-6, CMV or both
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The incidence of HHV-6 active infection in the present 
study was also relatively lower (26%) than that observed 
in other solid organ transplant centers (31-50%).5,7,8,10,14 
Nevertheless, the technical methodology applied and 
social and economic factors were not considered in 
these analyses. The time of diagnosis could be another 
difference. Strategically, we investigated HHV-6 active repli-
cation between the 1st and the 6th week post-transplantation 
because this is the period with greater risk. According to some 
authors, this is the period when the majority of primary infec-
tions are seen, usually developing into severe diseases with 
involvement of end-organs. This is also the risk period for 
secondary disease by HHV-6 virus, appearing generally from 
the 2nd to the 6th week post-transplantation, which was 
exactly what was observed in this study.1,2,11,17,18 
No clinical or transplant-related factor appears to be 
clearly associated with early HHV-6 replication. However, as 
it was expected, prophylaxis or treatment with anti-CD3 has 
already been described as an independent risk factor.12,23 
The clinical importance of HHV-6 among liver recipients 
is well documented, mainly because the major signs/
symptoms related to this infection are also the traditional 
presentation of graft dysfunction, imposing specific 
differential diagnosis. Besides hepatitis and liver graft loss, 
HHV-6 can cause meningoencephalitis due to its peculiar 
neuroinvasive potential and predisposition for opportunistic 
infections.1,9,17,20,22,24 Although acute onset of neurological 
symptoms is not common early after kidney transplant, 
HHV-6 might be an important differential diagnosis whenever 
a meningoencephalitis occurs after transplantation.1,4,5,11,18
Many authors have explored the indirect effects of 
HHV-6, mainly simultaneously with CMV infection, with 
contradictory results. Some of them described greater 
viral disease severity, while others did not find it.14-16,24,25 
Recently, Humar et al. showed that co-infection with 
HHV-6 can compromise CMV disease outcomes  treated 
with ganciclovir or valganciclovir, being associated with 
frequent recurrence of replication.23 
In order to clarify if early HHV-6 infection could affect CMV 
active replication between the 4th and the 12th week post-kidney 
transplant, the present study showed that it did not increase 
the incidence of CMV infection nor its severity. Besides the 
sample size, the apparent low clinical impact of early HHV-6 
replication among the studied population could result from the 
strict preemptive strategy on CMV monitoring and treatment. In 
this study, patients were followed under preemptive strategy for 
CMV according to the previously defined Ag cut-off of 10 positive 
cells for starting ganciclovir treatment. As many other viruses, 
CMV and HHV-6 can have similar clinical manifestations at the 
beginning, making it hard to tease out the role of each virus 
in a mild syndrome, especially under immunossuppresion. 
The stratification of the analysis and the combination of a 
sensitive and specific laboratory tool were applied to identify 
any independent effect of both viruses.13 It is probable that 
diagnosing or treating CMV infection only in symptomatic 
patients could better reveal a negative interaction of these 
viruses.3 This is supported by reports showing some degree of 
HHV-6 response to ganciclovir, even though no specific anti-
HHV-6 treatment is available until now.24,25 
In the present study, every HHV-6 VL was considered 
significant, and it was associated with higher incidence of 
bacterial and fungal infections, besides more hospitalizations 
with longer duration during the first 6 and 12 months post-
transplantation. It was not clear if these infections were cause 
or consequence of the longer hospitalizations. Clarifying this 
association is extremely valuable because, at least in liver 
transplantation, fungal infections have been the major cause 
of morbidity and mortality related to the HHV-6 infection.1,17,22 
Even though there was no case of severe fungal infection 
among the studied kidney recipients justifying greater 
necessity for hospitalization, toxicity of antifungal drugs and/
or their pharmacological interaction with immunosuppressive 
drugs might be considered. Some drugs were also associated 
with other infections. The paradoxical effect of MMF was 
interesting, apparently increasing the risk of CMV and 
decreasing the risk of fungal infection. The independence of 
all these factors can only be checked by a multivariate analysis 
in studies with larger sample size.
The low immunological risk of the selected patient 
population (adults receiving a first graft) and the small 
sample size were limitations of the present study. However, 
the use of two different methodologies to evaluate HHV-6 
and CMV, respectively was perhaps the major limitation. 
Both Ag and qPCR are well recognized for this purposes, but 
measure different aspects of the same condition – the viral 
replication.1,23,26-28 The way to attenuate this bias would be 
to apply a qualitative analysis, but it could still compromise 
the analysis of the association between two viral infections. 
The clinical meaning of low viral activity has been difficult 
to interpret, mainly when the aim is to avoid signs/symptoms. 
Concerning the Ag, we previously determined that 10 positive 
cells is a risk for pCMV disease, suggesting that treatment 
would indicated.13 This cut-off of cells when analyzed by 
qPCR corresponds to > 7000 copies/mL of whole blood, quite 
similar to that which has been practiced by other centers 
worldwide. It is important to note that sometimes, at least 
for CMV, VL up to 3000 copies/mL can not be detected by Ag 
test.9 Then, it would be reasonable to consider that the low 
HHV-6 VLs found in this study (indicating low viral replication 
rate) could explain the benign presentation of the registered 
events. However, as of this moment there is no study defining 
clinically the HHV-6 VL level that could differentiate latency 
from active viral replication.29 Corroborating the presented 
results, an important study recently published by Humar et al. 
describes 31% of HHV-6 active infection among 253 patients 
under CMV disease treatment. They found a median highest 
VL of 281 copies/mL of whole blood, being seldom as high as 
100.000 copies/mL.12,23 
Finally, this study showed that early HHV-6 replication 
after kidney transplant appears to be weakly significant, 
even though it was associated with more bacterial and fungal 
infections, more hospital admissions and longer duration 
of hospitalization. These evidence suggest that HHV-6 is not 
an innocuous virus, and probably is a marker of excessive 
immunosuppression.4,15,16,24 Nevertheless, there is no reason 
for systematic follow-up of this virus, at least in patients under 
preemptive monitoring for CMV. Until now, there is no evidence 
for HHV-6 worsening CMV outcomes in the highest risk period, 
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even though its interference with treatment outcome of pDCMV 
with ganciclovir should be confirmed in larger studies. HHV-6 
was not associated with graft dysfunction or graft loss/death in 
the first year after kidney transplant.
Conclusion
Latent HHV-6 infection is highly prevalent (> 80%), being 
more common among kidney transplant candidates than 
healthy donors. The incidence of early active infection after 
transplantation is 26%. Despite not affecting CMV prognosis, 
it is associated with more bacterial and fungal infections and 
longer duration of hospitalization in the first 6 and 12 months. 
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